title: The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study.
abstract: OBJECTIVE
  In the cortex of animals, serotonin (5-HT) levels increase after several weeks of treatment with selective serotonin reuptake inhibitors (SSRIs). Studies using an intrasubject design to examine the effects of SSRI treatment on 5-HT(2A) receptors in the cortex of drug-free depressed patients are needed. In theory, agonist stimulation of 5-HT(2A) receptors could be relevant to SSRI treatment by promoting neuronal growth and survival as well as direct elevation of mood. The objective of this study was to evaluate the effect of 6 weeks of paroxetine treatment on 5-HT(2A) receptors in depressed patients.
  
  
  METHODS
  After a medication-free period of at least 3 months, 19 depressed patients were treated for 6 weeks with paroxetine, 20 mg/day. The authors used [(18)F]setoperone and positron emission tomography to assess 5-HT(2A) receptor binding potential in the patients before and after treatment and in 19 age-matched healthy subjects.
  
  
  RESULTS
  5-HT(2A) binding potential declined with age in all cortical regions in the depressed and healthy subjects. There was a significant interaction between age and treatment effect on 5-HT(2A) binding potential in all cortical regions. Subjects aged 20 to 30 years had a 10% decrease in 5-HT(2A) binding potential after treatment, whereas subjects aged 30 to 40 had no change. No regional differences in 5-HT(2A) binding potential between depressed and healthy subjects were found.
  
  
  CONCLUSIONS
  5-HT(2A) receptors down-regulate in young depressed subjects after treatment with paroxetine, but this down-regulation attenuates with age. This suggests that over 6 weeks paroxetine treatment increases 5-HT agonism on 5-HT(2A) receptors in the cortex of young patients with depression.
authors.affiliation: Clarke Division, Centre for Addictions and Mental Health, Department ofPsychiatry, University of Toronto, Ontario, Canada. jmeyer@camhpet.on.ca
authors.forename: J H
authors.initials: JH
authors.lastname: Meyer
authors.forename: S
authors.initials: S
authors.lastname: Kapur
authors.forename: B
authors.initials: B
authors.lastname: Eisfeld
authors.forename: G M
authors.initials: GM
authors.lastname: Brown
authors.forename: S
authors.initials: S
authors.lastname: Houle
authors.forename: J
authors.initials: J
authors.lastname: DaSilva
authors.forename: A A
authors.initials: AA
authors.lastname: Wilson
authors.forename: S
authors.initials: S
authors.lastname: Rafi-Tari
authors.forename: H S
authors.initials: HS
authors.lastname: Mayberg
authors.forename: S H
authors.initials: SH
authors.lastname: Kennedy
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002540:Cerebral Cortex / Q000000981:diagnostic imaging* / Q000187:drug effects* / Q000378:metabolism; D003866:Depressive Disorder / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000494:pharmacology / Q000627:therapeutic use*; D011744:Pyrimidinones; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D014055:Tomography, Emission-Computed / Q000706:statistics & numerical data; D016896:Treatment Outcome
chemical_list: D005462:Fluorine Radioisotopes; D017374:Paroxetine; D011744:Pyrimidinones; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; C045359:setoperone